Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.52 |
| ▸ | NOS1 | P29475 | 4/20 | 0.52 |
| ▸ | NOS3 | P29474 | 3/20 | 0.52 |
| ▸ | NOS2 | P35228 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285415 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL29150937 | 0.84 | CYP1A2 (0.58) | CYP1A2CYP2C19HRH4NOS1NOS3 | |
| SCHEMBL11880033 | 0.81 | TSHR (0.48) | CYP1A2TDP1ALDH1A1TSHRHSD17B10 | |
| Thiourea SCHEMBL30543065 | 0.80 | CYP1A2 (0.65) | CYP1A2CYP2C19HRH4NOS1NOS3 | |
| Hydrochloric Acid SCHEMBL8997526 | 0.78 | NOS1 (0.54) | CYP1A2CYP2C19HRH4NOS1NOS3 | |
| SCHEMBL9710137 | 0.77 | CYP1A2 (0.75) | CYP1A2TDP1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL16223462 | 0.77 | TSHR (0.50) | TDP1ALDH1A1TSHRHSD17B10LMNA | |
| Adipic Acid SCHEMBL1071331 | 0.75 | LMNA (0.69) | CYP1A2TDP1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL9193111 | 0.75 | CYP1A2 (0.71) | CYP1A2CYP2C19HRH4NOS1NOS3 | |
| Glutarate SCHEMBL4148651 | 0.75 | SLC22A6 (0.69) | CYP1A2ALDH1A1TSHRLMNASLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10251392-B2 | Antimicrobial devices and compositions | AVENT, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016176636-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2015168465-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | disclosed |
| EP-1781098-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006015317-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | CYP1A2 4191/4885CYP2C19 2097/4885HRH4 4176/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | CYP1A2 3361/4885CYP2C19 1838/4885HRH4 4614/4885 |
| US-10251392-B2 | Antimicrobial devices and compositions | AAAS, AOC1, COL14A1 | CYP1A2 3226/4885CYP2C19 2513/4885HRH4 3182/4885 |
| US-10308597-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | CYP1A2 3361/4885CYP2C19 1838/4885HRH4 4614/4885 |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AAAS, AOC1, COL14A1 | CYP1A2 3226/4885CYP2C19 2513/4885HRH4 3182/4885 |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | CYP1A2 3361/4885CYP2C19 1838/4885HRH4 4614/4885 |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | CYP1A2 3361/4885CYP2C19 1838/4885HRH4 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.